Poolbeg Prepares for POLB-001 Phase 2a Trial in Cancer Patient
Poolbeg is preparing to launch Phase 2A trial of POLB-001 for cytokine release syndrome. ACT has been appointed to run the study, with The Christie NHS Trust and other UK centres selected. First-patient dosing is pending, with interim data expected summer 2026.
#POLB #Biotech #Investing #SmallCaps
Видео Poolbeg Prepares for POLB-001 Phase 2a Trial in Cancer Patient канала Emerging Edge
#POLB #Biotech #Investing #SmallCaps
Видео Poolbeg Prepares for POLB-001 Phase 2a Trial in Cancer Patient канала Emerging Edge
Комментарии отсутствуют
Информация о видео
4 октября 2025 г. 17:42:43
00:00:35
Другие видео канала
Wishbone Gold – Waiting on Red Setter Drill Results
UK Oil & Gas – £3 Million Raise to Power Hydrogen Future
United Oil & Gas – Leaner and Focused in 2025
Blue Star Capital – SatoshiPay Publishes Treasury Strategy
ECR Minerals – Blue Mountain Drilling and Discovery
Greatland Gold Delivers Strong Q3 Production and Cash Growth
ECR Minerals – Advancing Gold in Australia
Poolbeg Pharma: The £26m Biotech Targeting Cancer & Obesity
Orosur Mining – C$20 Million Raised in Private Placement
Reabold Secures €16 Million Earn-Out Deal for Colle Santo
Richtech Robotics – Changing How We Work
United Oil & Gas Raises Funds to Kick-Off Piston Coring in Jamaica
United Oil & Gas – Jamaica: 7 Billion Barrels Potential
Poolbeg’s POLB-001 Gets FDA Orphan Drug Designation
Gold Could Break $4,000 Amid Global Instability
£10m Cash in the Bank: Poolbeg Funded Into 2027
Bezant Resources Rises on Blackstone Share Sale
Wishbone Gold – Expanding Drilling at Red Setter
United Oil & Gas – NPV of $23 Billion Unrisked
The Smarter Web Company Secures £9.7 Million Including Insitutional Support
